Section Arrow
EYPT.NASDAQ
- EyePoint Inc.
Quotes are at least 15-min delayed:2026/07/07 15:22 EDT
Regular Hours
Last
 13.79
-0.65 (-4.50%)
Day High 
14.85 
Prev. Close
14.44 
1-M High
15.92 
Volume 
1.53M 
Bid
13.78
Ask
13.79
Day Low
13.73 
Open
14.65 
1-M Low
11.295 
Market Cap 
1.17B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.99 
20-SMA 13.22 
50-SMA 13.18 
52-W High 19.11 
52-W Low 9.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.51/-3.17
Enterprise Value
1.19B
Balance Sheet
Book Value Per Share
2.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
31.37M
Operating Revenue Per Share
0.37
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRNXCrinetics Pharmaceuticals83.445+41.415+98.54%-- 
TVRDTvardi Therapeutics Inc3.08+1.07+53.23%-- 
RXRXRecursion Pharmaceuticals3.93-0.03-0.76%-- 
TOVXTheriva Biologics Inc0.2379-0.0154-6.08%-- 
GOSSGossamer Bio0.177-0.0179-9.18%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.